Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bjd/ljad076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ruthenium-106 brachytherapy and central uveal melanoma.
Int Ophthalmol
January 2025
Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.
View Article and Find Full Text PDFReply to Pennington, T.E.; Thompson, J.F. Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on "Dixon et al. Primary Cutaneous Melanoma-Management in 2024. 2024, , 1607".
J Clin Med
January 2025
Department of Surgery, Formerly of Royal Marsden Hospital, London SW3 6JJ, UK.
We note with interest the commentary by Pennington and Thompson (P&T) regarding our detailed update on the management of primary cutaneous melanoma in 2024 [...
View Article and Find Full Text PDFSentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. 2024, , 1607.
J Clin Med
January 2025
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.
Management of melanoma in 2024 requires at times complex decision making and a multidisciplinary approach. An article by Dixon and collaborators published in this Journal contained broad-reaching recommendations, some of which are in contradiction of accepted National and International Guidelines. This article seeks to highlight these points of contention and outline widely accepted standards of care that are considered best practice.
View Article and Find Full Text PDFAdjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse.
Cancers (Basel)
January 2025
Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Spain.
Background: Anti-PD-1-based immunotherapy has improved outcomes in stage IIB to IV resected melanoma patients in clinical trials. However, little is known about real-world outcomes, prognostic factors and patterns of relapse.
Methods: This is a retrospective multicenter observational study including patients with resected melanoma treated with subsequent anti-PD-1-based adjuvant immunotherapy.
Cutaneous Nevoid Melanoma: A Retrospective Study on Clinico-Pathological Characteristics, with a Focus on Dermoscopic Features and Survival Analysis.
Cancers (Basel)
December 2024
Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Diagnosis of nevoid melanoma (NeM) is often difficult because NeM closely resembles a common nevus clinically and histologically. A retrospective study was conducted on 110 patients diagnosed with and/or treated for primary nevoid melanoma at the Veneto Institute of Oncology and at the University Hospital of Padua from August 1999. Mean Breslow thickness was of 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!